Research programme: antithrombotics therapeutics- Aplagon/ Cadila Pharmaceuticals

Drug Profile

Research programme: antithrombotics therapeutics- Aplagon/ Cadila Pharmaceuticals

Alternative Names: APAC

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aplagon
  • Class Anticoagulants; Antiplatelets; Antithrombotics
  • Mechanism of Action Heparin antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 19 Sep 2017 Aplagon in collaboration with Cadila pharmaceuticals plans a phase I/II and phase II/III trials for Thrombosis (Prevention) in India in 2019
  • 19 Sep 2017 Preclinical trials in Thrombosis (Prevention) in Finland (unspecified route)
  • 19 Sep 2017 Cadila Pharmaceuticals plans to pursue fast track indication from USFDA for Thrombosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top